Our initial therapeutic candidates have been designed to cross the blood brain barrier and modulate microglia in the brain to treat a range of immune-mediated and mitochondrial diseases, starting with amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, and other indications (e.g. Frontotemporal Dementia (FTD), Huntington’s Disease, Friedreich’s Ataxia, Muscular Dystrophy, Parkinson’s, and Alzheimer’s disease).
Because our platform targets such fundamental cell energy modulators, like PGC1α, present in all mammalian cells, it appears to have clinical utility across a broad range of immune-mediated and mitochondrial diseases—beyond the CNS.
TQS-168 ALS and exploratory development ongoing in Frontotemporal Dementia, Huntington’s Disease, Muscular Dystrophy, Friedreich’s Ataxia and other indications
